CRISPR Therapeutics (CRSP) total debt

Total debt · fiscal 2025
$206.75M

CRISPR Therapeutics (CRSP) carried total debt of $206.75M at the end of fiscal 2025 (December 31, 2025). That is 7.6% lower than the $223.69M of fiscal 2024. Figures as of 18 Nov 2026, 08:15 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total debt, fiscal 2025
$206.75M
Change on fiscal 2024
−7.6%
Highest on record
$244.02Mfiscal 2022
Lowest on record
$206.75Mfiscal 2025
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

CRISPR Therapeutics total debt, in more detail

Across the 4 fiscal years on record (2022–2025), the highest was $244.02M in fiscal 2022 and the lowest $206.75M in fiscal 2025.

Total debt was 0.1× shareholders' equity at the end of fiscal 2025.

History · 4 fiscal years

Total debt by fiscal year

CRISPR Therapeutics total debt, year by year

CRISPR Therapeutics (CRSP) total debt by fiscal year
Fiscal yearTotal debtChangeYear endedDebt ÷ equity
2025$206.75M 7.6% down0.1×
2024$223.69M 6.3% down0.1×
2023$238.63M 2.2% down0.1×
2022$244.02M—0.1×

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.

How to read it

Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.

Total debt at health care companies of similar size

Total debt of CRISPR Therapeutics and comparable companies
CompanyTotal debtFiscal year
MiniMed Group MMED$145.00M2026
Adaptive Biotechnologies ADPT$79.15M2025
Heartflow HTFL$22.05M2025
CRISPR Therapeutics CRSP$206.75M2025
Travere Therapeutics TVTX$328.73M2025
Option Care Health OPCH$1.27B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on CRSP

CRISPR Therapeutics, figure by figure

CRISPR Therapeutics (CRSP) overview: price, valuation and scorecardAll health care companies by market value

CRISPR Therapeutics total debt: questions and answers

How much debt does CRISPR Therapeutics have?

CRISPR Therapeutics (CRSP) carried total debt of $206.75M at the end of fiscal 2025 (December 31, 2025). That is 7.6% lower than the $223.69M of fiscal 2024.

What are the highest and lowest total debt figures on record for CRISPR Therapeutics?

Across the 4 fiscal years on record (2022–2025), the highest was $244.02M in fiscal 2022 and the lowest $206.75M in fiscal 2025.

How does CRISPR Therapeutics's debt compare with its equity?

Total debt was 0.1× shareholders' equity at the end of fiscal 2025.

How is CRISPR Therapeutics's total debt calculated?

Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “CRISPR Therapeutics (CRSP) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/CRSP/total-debt

Underlying data: the company's filings with the SEC and Yahoo Finance.